Production of High-Yield Adeno Associated Vector Batches Using HEK293 Suspension Cells

被引:0
|
作者
Pietersz, Kimberly L. [1 ]
Nijhuis, Paul J. H. [1 ]
Klunder, Matthijs H. M. [1 ]
van den Herik, Joelle [1 ]
Hobo, Barbara [1 ]
de Winter, Fred [1 ]
Verhaagen, Joost [1 ,2 ]
机构
[1] Vrije Univ Amsterdam, Netherlands Inst Neurosci, Royal Netherlands Acad Arts & Sci KNAW, Lab Regenerat Sensorimotor Syst, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Ctr Neurogenom & Cognit Res, Amsterdam Neurosci, Amsterdam, Netherlands
来源
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS | 2024年 / 206期
关键词
GENE DELIVERY; NEURONS;
D O I
10.3791/66532
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Adeno-associated viral vectors (AAVs) are a remarkable tool for investigating the central nervous system (CNS). Innovative capsids, such as AAV.PHP.eB, demonstrate extensive transduction of the CNS by intravenous injection in mice. To achieve comparable transduction, a 100 -fold higher titer (minimally 1 x 10 11 genome copies/mouse) is needed compared to direct injection in the CNS parenchyma. In our group, AAV production, including AAV.PHP.eB relies on adherent HEK293T cells and the triple transfection method. Achieving high yields of AAV with adherent cells entails a labor- and material -intensive process. This constraint prompted the development of a protocol for suspension -based cell culture in conical tubes. AAVs generated in adherent cells were compared to the suspension production method. Culture in suspension using transfection reagents Polyethylenimine or TransIt were compared. AAV vectors were purified by iodixanol gradient ultracentrifugation followed by buffer exchange and concentration using a centrifugal filter. With the adherent method, we achieved an average of 2.6 x 10 12 genome copies (GC) total, whereas the suspension method and Polyethylenimine yielded 7.7 x 10 12 GC in total, and TransIt yielded 2.4 x 10 13 GC in total. There is no difference in in vivo transduction efficiency between vectors produced with adherent compared to the suspension cell system. In summary, a suspension HEK293 cell based AAV production protocol is introduced, resulting in a reduced amount of time and labor needed for vector production while achieving 3 to 9 times higher yields using components available from commercial vendors for research purposes.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Development and improvement of a serum-free suspension process for the production of recombinant adenoviral vectors using HEK293 cells
    Tsao, YS
    Condon, R
    Schaefer, E
    Lio, P
    Liu, Z
    CYTOTECHNOLOGY, 2001, 37 (03) : 189 - 198
  • [42] Development and improvement of a serum-free suspension process for the production of recombinant adenoviral vectors using HEK293 cells
    Yung-Shyeng Tsao
    Russell Condon
    Eugene Schaefer
    Peggy Lio
    Zhong Liu
    Cytotechnology, 2001, 37 : 189 - 198
  • [43] Transient gene expression in suspension HEK293 cells: Application to large-scale protein production
    Baldi, L
    Jacquet, R
    Picasso, S
    Tromba, P
    Derow, E
    Girard, P
    Hacker, D
    Wurm, FM
    ANIMAL CELL TECHNOLOGY MEETS GENOMICS, 2005, : 365 - 367
  • [44] Scalable recombinant adeno-associated virus (rAAV) production in HEK293 cells with histidine-rich peptide as transfection reagent
    Perevoshchikova, I.
    Arslan, B.
    Gardin, J.
    Bourbon, P.
    Arabshahi, H.
    Cinek, T.
    Shroff, S.
    Femenia, J.
    Tang, Y.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A102 - A102
  • [45] Combination of Advanced Plasmid Design, Transfection Reagent and Design of Experiment (DOE) Achieves High-Yield, High-Quality and Potent AAV Vectors in Scalable Suspension HEK293 Cells
    Liao, Jing
    Reuter, Hans
    Wu, Carmen
    Deng, June
    Chen, Yinxing
    Walsh, Noel
    Lee, William
    Hu, Shiliang
    Jia, Nannan
    Vaishampayan, Priyanka
    Zhou, Ruohong
    Bastille, Amy
    Xiong, John
    DiGioia, Nicholas
    Kerrick, Jeremy
    Drouin, Lauren
    Hebben, Matthias
    MOLECULAR THERAPY, 2022, 30 (04) : 410 - 410
  • [46] Scalable and high-titre lentiviral vector production from cGMP-compliant clonal suspension HEK293 cell line
    Krakowiak, J.
    Tomas, H.
    Keller, L. E.
    Efstathiou, A.
    Parker-Manuel, R.
    Macchiarulo, E.
    Zhang, L.
    Liu, Q.
    Cawood, R.
    Payne, T.
    HUMAN GENE THERAPY, 2019, 30 (11) : A32 - A33
  • [47] Development of a Serum-Free Suspension HEK293 Cell Line for AAV Production with High Yield and Low Encapsidated DNA Impurities
    Yang, Hairui
    MOLECULAR THERAPY, 2024, 32 (04) : 511 - 511
  • [48] Development of an Assay to Perform High-Throughput Drug Screen in HEK293 Cells to Improve AAV Vector Production
    Panthi, Santosh
    Baer, Alan
    Bhattarai, Nirjal
    MOLECULAR THERAPY, 2024, 32 (04) : 711 - 711
  • [49] Production of Recombinant Adeno-Associated Virus Through High-Cell-Density Transfection of HEK293 Cells Based on Fed-Perfusion Culture
    Deng, Zhe
    Lv, Yan-Ling
    Wang, Xin-Tao
    Yuan, Long-Hui
    Zhao, Kai
    Du, Zeng-Min
    Xiao, Xiao
    HUMAN GENE THERAPY, 2025,
  • [50] Lentiviral Vector Production Using Suspension Adapted HEK293T Cells in Serum Free Media
    Welty, Matthew B.
    Thirumala, Sreedhar
    Beck, Madelyn
    House, Kimberley
    Lin, Tsai-Yu
    Shaw, Aaron M.
    Moore, Alisha
    Trinh, Quynh Mai
    Hopewell, Emily L.
    Bischof, Daniela
    Cornetta, Kenneth
    MOLECULAR THERAPY, 2023, 31 (04) : 152 - 153